Parexel, a global clinical development partner, has unveiled ParexelAI, a proprietary suite of human-led AI services and capabilities designed to enhance speed, quality, and operational efficiency across clinical development programs.

ParexelAI integrates the company’s AI-powered tools and platforms with human oversight and transparency throughout the clinical development lifecycle, spanning early-stage trials to post-market surveillance. 

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities to support sponsors, research sites, and patients.

Peyton Howell, Chief Executive Officer of Parexel, said, “ParexelAI represents years of deep technology integration, all in service of helping our customers deliver life-changing treatments to patients. We have a responsibility to continually evolve by advancing our capabilities, strengthening our partnerships and innovating in ways that help sponsors run faster, more effective trials.”

Rob Goodwin, Chief Operating Officer at Parexel, said, “Our tools automate previously manual work that slows teams down, enabling our experts to increase quality and consistency, surface even more insights for our customers and further improve operational excellence.”

Tala Fakhouri, Chief AI & Regulatory Strategy Officer at Parexel, said, “AI delivers its greatest value when it amplifies human expertise. Our human-in-the-lead model ensures quality, compliance and patient safety at every stage of the trial lifecycle. With ParexelAI, we’re able to apply these insights in real-time to improve every trial”